Supplemental Table S1. Background Annual Incidence Rates of Events Among Nursing Home Residents during 2020, Prior to Administration of the COVID-19 Vaccine

			Previous SARS-CoV-2 infection				Immunocompromised		
	Overall N=43,371		No N=37,408		Yes N=5,963		No N=39,966		Yes N=3,405	
	n	Per 100,000 PY	n	Per 100,000 PY	n	Per 100,000 PY	n	Per 100,000 PY	n	Per 100,000 PY
Total										
Acute Disseminated Encephalomyelitis (ADEM)	1	16.1 (2.3, 114.5)	1	20.2 (2.8, 143.2)	0		1	17.8 (2.5, 126.4)	0	
Acute Myocardial Infarction (AMI)	29	467.8 (325.1, 673.1)	29	585.1 (406.6, 841.9)	0		28	498.8 (344.4, 722.4)	1	170.6 (24.0, 1210.9)
Anaphylaxis	1	16.1 (2.3, 114.5)	1	20.2 (2.8, 143.2)	0		1	17.8 (2.5, 126.4)	0	
Appendicitis	4	64.5 (24.2, 171.8)	4	80.7 (30.3, 214.9)	0		4	71.2 (26.7, 189.8)	0	
Bell's Palsy	3	48.4 (15.6, 150.0)	2	40.3 (10.1, 161.3)	1	80.4 (11.3, 571.0)	3	53.4 (17.2, 165.6)	0	
Convulsions/Seizures	14	225.7 (133.7, 381.2)	14	282.4 (167.2, 476.7)	0		12	213.7 (121.4, 376.3)	2	341.3 (85.3, 1364.5)
Disseminated Intravascular Coagulation	1	16.1 (2.3, 114.5)	1	20.2 (2.8, 143.2)	0		1	17.8 (2.5, 126.4)	0	
Guillain-Barré syndrome (GBS)	2	32.2 (8.1, 128.9)	2	40.3 (10.1, 161.3)	0		2	35.6 (8.9, 142.4)	0	
Myocarditis/pericarditis	1	16.1 (2.3, 114.5)	1	20.2 (2.8, 143.2)	0		1	17.8 (2.5, 126.4)	0	
Stroke, hemorrhagic	11	175.3 (97.1, 316.5)	11	221.9 (122.9, 400.6)	0		9	160.3 (83.4, 308.0)	2	341.2 (85.3, 1364.4)
Stroke, ischemic	66	1068.4 (840.9, 1357.4)	64	1291.9 (1011.2, 1650.5)	2	160.9 (40.2, 643.4)	63	1122.8 (877.1, 1437.3)	3	512.0 (165.1, 1587.6)
Venous thromboembolism (VTE)	48	765.3 (576.8, 1015.6)	44	888.0 (660.8, 1193.3)	4	321.9 (120.8, 857.8)	42	748.4 (553.1, 1012.7)	6	1024.9 (460.5, 2281.4)
Pulmonary Embolism (PE)	25	398.4 (269.2, 589.6)	25	504.3 (340.7, 746.4)	0		23	409.7 (272.2, 616.5)	2	230.7 (57.7, 922.3)
Death	2654	42790 (41192, 44449)	2314	46662 (44799, 48603)	340	27345 (24598, 30412)	2406	42841 (41163, 44588)	248	42296 (37346, 47901)

PY: Person-Year

Note: Residents with a positive COVID-19 test within 20 days of study start date or on monoclonal antibodies within 90 days of study start date were excluded to prevent detection of adverse events attributable to viral infection or treatment.